短疗程头孢曲松治疗C3H小鼠伯氏疏螺旋体感染的疗效
Efficacy of short-course ceftriaxone therapy for Borrelia burgdorferi infection in C3H mice.
作者信息
Pavia Charles, Inchiosa Mario A, Wormser Gary P
机构信息
Division of Infectious Diseases, Department of Medicine, New York Medical College, Valhalla, New York 10595, USA.
出版信息
Antimicrob Agents Chemother. 2002 Jan;46(1):132-4. doi: 10.1128/AAC.46.1.132-134.2002.
Abstract
Ceftriaxone is highly effective clinically in patients with Lyme disease. We studied a representative invasive human isolate of Borrelia burgdorferi for which the MBC of ceftriaxone was 0.050 microg/ml. A once-per-day dosage regimen of ceftriaxone (50 mg/kg/dose) administered intramuscularly for 5 days was 100% effective in sterilizing tissue samples of C3H mice infected with this strain of B. burgdorferi, regardless of whether the mice were being treated concomitantly with a corticosteroid. Administration of the same five doses of ceftriaxone at 6-h intervals over just 24 h was also 100% effective. These experiments suggest that shorter courses of antibiotics than those currently recommended should be considered for study in patients with early uncomplicated Lyme disease.
摘要
头孢曲松在莱姆病患者的临床治疗中具有高效性。我们研究了一株具有代表性的侵袭性人类伯氏疏螺旋体分离株，其头孢曲松的最低杀菌浓度为0.050微克/毫升。对感染该株伯氏疏螺旋体的C3H小鼠，每天一次肌肉注射头孢曲松（50毫克/千克/剂量），连续注射5天，无论小鼠是否同时接受皮质类固醇治疗，在使组织样本除菌方面均有100%的效果。在仅仅24小时内每隔6小时给予相同的五剂头孢曲松，也有100%的效果。这些实验表明，对于早期无并发症的莱姆病患者，应考虑研究比目前推荐疗程更短的抗生素治疗方案。
相似文献
1
Efficacy of short-course ceftriaxone therapy for Borrelia burgdorferi infection in C3H mice.短疗程头孢曲松治疗C3H小鼠伯氏疏螺旋体感染的疗效
Antimicrob Agents Chemother. 2002 Jan;46(1):132-4. doi: 10.1128/AAC.46.1.132-134.2002.
2
Anti-tumor necrosis factor-alpha treatment activates Borrelia burgdorferi spirochetes 4 weeks after ceftriaxone treatment in C3H/He mice.在C3H/He小鼠中，头孢曲松治疗4周后，抗肿瘤坏死因子-α治疗可激活伯氏疏螺旋体。
J Infect Dis. 2007 May 15;195(10):1489-96. doi: 10.1086/513873. Epub 2007 Apr 6.
3
Efficacy of an evernimicin (SCH27899) in vitro and in an animal model of Lyme disease.埃维霉素（SCH27899）在体外及莱姆病动物模型中的疗效。
Antimicrob Agents Chemother. 2001 Mar;45(3):936-7. doi: 10.1128/AAC.45.3.936-937.2001.
4
Identifying Vancomycin as an Effective Antibiotic for Killing Borrelia burgdorferi.鉴定万古霉素为一种有效的抗杀伯氏疏螺旋体抗生素。
Antimicrob Agents Chemother. 2018 Oct 24;62(11). doi: 10.1128/AAC.01201-18. Print 2018 Nov.
5
Persistence of borrelial DNA in the joints of Borrelia burgdorferi-infected mice after ceftriaxone treatment.头孢曲松治疗后伯氏疏螺旋体感染小鼠关节中螺旋体 DNA 的持续存在。
APMIS. 2010 Sep 1;118(9):665-73. doi: 10.1111/j.1600-0463.2010.02615.x.
6
Antibiotic treatment in mice infected with Japanese Borrelia garinii: efficacy of ceftriaxone for eradicating the infection induced by Ixodes persulcatus tick bites.
Microbiol Immunol. 1997;41(2):165-8. doi: 10.1111/j.1348-0421.1997.tb01182.x.
7
In vivo activities of ceftriaxone and vancomycin against Borrelia spp. in the mouse brain and other sites.头孢曲松和万古霉素在小鼠脑及其他部位对疏螺旋体属的体内活性。
Antimicrob Agents Chemother. 1996 Nov;40(11):2632-6. doi: 10.1128/AAC.40.11.2632.
8
Generality of Post-Antimicrobial Treatment Persistence of Strains N40 and B31 in Genetically Susceptible and Resistant Mouse Strains.在遗传易感和抗性小鼠株中，菌株 N40 和 B31 在后抗生素治疗持续存在的普遍性。
Infect Immun. 2019 Sep 19;87(10). doi: 10.1128/IAI.00442-19. Print 2019 Oct.
9
Critical analysis of treatment trials of rhesus macaques infected with Borrelia burgdorferi reveals important flaws in experimental design.对感染伯氏疏螺旋体的恒河猴进行治疗试验的批判性分析揭示了实验设计中的重要缺陷。
Vector Borne Zoonotic Dis. 2012 Jul;12(7):535-8. doi: 10.1089/vbz.2012.1012. Epub 2012 May 23.
10
Erythema migrans after ceftriaxone treatment of aseptic meningitis caused by Borrelia burgdorferi.头孢曲松治疗伯氏疏螺旋体引起的无菌性脑膜炎后出现的游走性红斑。
Pediatr Infect Dis J. 2001 Oct;20(10):1010-2. doi: 10.1097/00006454-200110000-00022.
引用本文的文献
1
Persistent Borrelia burgdorferi Infection after Antibiotic Treatment: Systematic Overview and Appraisal of the Current Evidence from Experimental Animal Models.抗生素治疗后持续的伯氏疏螺旋体感染：来自实验动物模型的系统综述和当前证据评估。
Clin Microbiol Rev. 2022 Dec 21;35(4):e0007422. doi: 10.1128/cmr.00074-22. Epub 2022 Oct 12.
2
Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening.利用高通量筛选鉴定抗伯氏疏螺旋体的新型候选药物
Drug Des Devel Ther. 2016 Apr 1;10:1307-22. doi: 10.2147/DDDT.S101486. eCollection 2016.
3
Culture of the entire mouse to determine whether cultivable Borrelia burgdorferi persists in infected mice treated with a five-day course of Ceftriaxone.对整个小鼠进行培养，以确定在用头孢曲松进行为期五天的疗程治疗的感染小鼠中，是否仍存在可培养的伯氏疏螺旋体。
Antimicrob Agents Chemother. 2014 Nov;58(11):6701-3. doi: 10.1128/AAC.03751-14. Epub 2014 Aug 25.
4
Intraarticular corticosteroids in refractory childhood Lyme arthritis.关节内注射皮质类固醇治疗儿童难治性莱姆关节炎。
Rheumatol Int. 2014 Jul;34(7):987-94. doi: 10.1007/s00296-013-2923-9. Epub 2014 Jan 4.
5
Detection of Borrelia burgdorferi nucleic acids after antibiotic treatment does not confirm viability.抗生素治疗后检测到伯氏疏螺旋体核酸并不能确认其存活。
J Clin Microbiol. 2013 Mar;51(3):857-62. doi: 10.1128/JCM.02785-12. Epub 2012 Dec 26.
6
Spirochete antigens persist near cartilage after murine Lyme borreliosis therapy.螺旋体抗原在鼠莱姆病治疗后仍存在于软骨附近。
J Clin Invest. 2012 Jul;122(7):2652-60. doi: 10.1172/JCI58813. Epub 2012 Jun 25.
7
Ineffectiveness of tigecycline against persistent Borrelia burgdorferi.替加环素对持续性伯氏疏螺旋体无效。
Antimicrob Agents Chemother. 2010 Feb;54(2):643-51. doi: 10.1128/AAC.00788-09. Epub 2009 Dec 7.
8
Antibiotic treatment of animals infected with Borrelia burgdorferi.对感染伯氏疏螺旋体的动物进行抗生素治疗。
Clin Microbiol Rev. 2009 Jul;22(3):387-95. doi: 10.1128/CMR.00004-09.
9
Persistent arthritis in Borrelia burgdorferi-infected HLA-DR4-positive CD28-negative mice post-antibiotic treatment.抗生素治疗后，感染伯氏疏螺旋体的HLA - DR4阳性、CD28阴性小鼠出现持续性关节炎。
Arthritis Rheum. 2008 Dec;58(12):3892-901. doi: 10.1002/art.24028.
10
Outer surface protein A protects Lyme disease spirochetes from acquired host immunity in the tick vector.外表面蛋白A可保护莱姆病螺旋体免受蜱虫载体中宿主获得性免疫的影响。
Infect Immun. 2008 Nov;76(11):5228-37. doi: 10.1128/IAI.00410-08. Epub 2008 Sep 8.
本文引用的文献
1
Impact of genotypic variation of Borrelia burgdorferi sensu stricto on kinetics of dissemination and severity of disease in C3H/HeJ mice.狭义伯氏疏螺旋体的基因变异对C3H/HeJ小鼠传播动力学和疾病严重程度的影响。
Infect Immun. 2001 Jul;69(7):4303-12. doi: 10.1128/IAI.69.7.4303-4312.2001.
2
Efficacy of an evernimicin (SCH27899) in vitro and in an animal model of Lyme disease.埃维霉素（SCH27899）在体外及莱姆病动物模型中的疗效。
Antimicrob Agents Chemother. 2001 Mar;45(3):936-7. doi: 10.1128/AAC.45.3.936-937.2001.
3
Practice guidelines for the treatment of Lyme disease. The Infectious Diseases Society of America.莱姆病治疗实践指南。美国传染病学会。
Clin Infect Dis. 2000 Jul;31 Suppl 1:1-14. doi: 10.1086/314053.
4
Failure of treatment with cephalexin for Lyme disease.头孢氨苄治疗莱姆病失败。
Arch Fam Med. 2000 Jun;9(6):563-7. doi: 10.1001/archfami.9.6.563.
5
Efficacy of SCH27899 in an animal model of Legionnaires' disease using immunocompromised A/J mice.SCH27899在使用免疫受损A/J小鼠的军团病动物模型中的疗效。
Antimicrob Agents Chemother. 2000 May;44(5):1333-6. doi: 10.1128/AAC.44.5.1333-1336.2000.
6
In vivo activity and pharmacokinetics of ziracin (SCH27899), a new long-acting everninomicin antibiotic, in a murine model of penicillin-susceptible or penicillin-resistant pneumococcal pneumonia.新型长效埃弗米星抗生素齐拉星（SCH27899）在青霉素敏感或耐药肺炎球菌肺炎小鼠模型中的体内活性及药代动力学
Antimicrob Agents Chemother. 2000 Apr;44(4):1010-8. doi: 10.1128/AAC.44.4.1010-1018.2000.
7
Status of Borrelia burgdorferi infection after antibiotic treatment and the effects of corticosteroids: An experimental study.抗生素治疗后伯氏疏螺旋体感染状况及皮质类固醇的影响：一项实验研究。
J Infect Dis. 2000 Mar;181(3):1069-81. doi: 10.1086/315340.
8
Activity of sera from patients with Lyme disease against Borrelia burgdorferi.
Clin Infect Dis. 1997 Jul;25 Suppl 1:S25-30. doi: 10.1086/516168.
9
In vivo activities of ceftriaxone and vancomycin against Borrelia spp. in the mouse brain and other sites.头孢曲松和万古霉素在小鼠脑及其他部位对疏螺旋体属的体内活性。
Antimicrob Agents Chemother. 1996 Nov;40(11):2632-6. doi: 10.1128/AAC.40.11.2632.
10
In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics.来自不同来源的30株疏螺旋体菌株对8种抗微生物化疗药物的体外敏感性。
Infection. 1996 Jan-Feb;24(1):60-3. doi: 10.1007/BF01780660.
Zotero 插件